Amgen Inc. (AMGN) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

My name is Julie Ann, and I will be your conference facilitator today for the Amgen Q2 twenty twenty six Earnings Conference Call. All lines have been placed on mute to prevent any background noise. There will be a question and answer session at the conclusion of the last speaker's prepared remarks. In order to ensure that everyone has a chance to participate, we would like to request that you limit yourself to asking one question during the Q and A session. I would now like to introduce Casey Caparelli, Vice President of Investor Relations. Mr. Caparelli, you may now begin. Thank you, Julianne. Good afternoon, everyone, and welcome to our second quarter of twenty twenty six earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Murdo Gordon, Jay Bradner, and Peter Griffith. Through the course of our discussion today, we will use non GAAP financial measures to describe our performance and have provided appropriate reconciliations within the materials that accompany this call. We will also make some forward looking statements, which are qualified by our Safe Harbor statement. And please note that actual results can vary materially. Over to you, Bob. Good afternoon and thank you for joining us. Our strong results were driven by the breadth and depth of our portfolio and once again demonstrate our ability to grow through patent expirations and increased competition. We're pleased with the momentum across our business and expect to reach more patients with our innovative medicines and biosimilars in the second half of the year than ever before as volume demand for our products continues to grow strongly. This broad based performance is exactly what our strategy is intended to deliver and it's why we remain confident ...